-
Mashup Score: 10
Abstract. Purpose: Breast cancer cells disseminate to distant sites via Tumor Microenvironment of Metastasis (TMEM) doorways. The TIE2 inhibitor rebastinib blocks TMEM doorway function in the PyMT mouse model of breast cancer. We aimed to assess the safety and pharmacodynamics of rebastinib plus paclitaxel or eribulin in patients with HER2-negative metastatic breast cancer (MBC). Patients and Methods: This phase Ib trial enrolled 27 patients with MBC who received 50 mg or 100 mg of rebastinib PO BID in combination with weekly paclitaxel 80 mg/m2 (if ≤ 2 prior non-taxane regimens) or eribulin 1.4 mg/m2 on days 1 & 8 (if ≥ 1 prior regimen). Safety, tolerability and pharmacodynamic parameters indicating TIE2 kinase inhibition and TMEM doorway function were evaluated. Results: No dose-limiting toxicities in cycle 1 or 2 were observed among the first 12 patients at either rebastinib dose level. The most common treatment-emergent adverse events (AEs) were anemia (85%), fatigue (78%), anorexi
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 32Treatment and Survival Differences between Patients with Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma of the Breast - 16 day(s) ago
AbstractBackground:. Invasive lobular carcinoma (ILC) exhibits differences in molecular and biological characteristics compared with invasive ductal carcinoma (IDC). We aim to compare breast cancer–specific survival (BCSS) between patients with ILC and IDC.Methods:. We used data from the Surveillance, Epidemiology, and End Results database (1992–2020). Logistic regression analyses were conducted to identify factors associated with treatment modalities. We examined BCSS at different time points using a cox regression model with time-dependent coefficient.Results:. A total of 343,397 patients with IDC and 39,859 patients with ILC were included. Patients with ILC had more advanced-stage disease (stage II, 35% vs. 34%; stage III, 16% vs. 11%) and a higher rate of hormone receptor–positive disease (97% vs. 81%). Compared with patients with IDC, patients with ILC had better BCSS in the first five years (HR = 0.71; P < 0.001) but worse BCSS in later years (HR = 1.30, P < 0.001 in years 6–10;
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
Some studies reported better survival for lobular breast cancer compared to ductal breast cancer. Other studies have reported the opposite. Our @MontefioreNYC team evaluated population data to answer it. Hint: Time matters @OncoAlert #BCSM @EinsteinMed https://t.co/tpTPwGEmRX
-
-
Mashup Score: 0Texas Gov. Abbott designates Venezuelan gang, Tren de Aragua, as a foreign terrorist organization - 2 month(s) ago
Texas Gov. Greg Abbott announced the state is going to target a Venezuelan gang that he said was notorious for brutal violence and murder and posed a threat to Texans’ safety.
Source: www.foxnews.comCategories: General Medicine News, Oncologists1Tweet-
Texas Gov. Abbott designates Venezuelan gang, Tren de Aragua, as a foreign terrorist organization https://t.co/Me4bk9cYxy #FoxNews
-
-
Mashup Score: 0President Joe Biden drops out of 2024 presidential race - 4 month(s) ago
Biden, after a five-decade political career, faced a reckoning over his age and whether he could defeat Donald Trump. His party now faces a historic effort to replace him.
Source: www.nbcnews.comCategories: General Medicine News, Oncologists1Tweet-
President Joe Biden drops out of 2024 presidential race https://t.co/wJRLM6QL6P via @nbcnews
-
-
Mashup Score: 1
Curious to learn more about the SOAP process, but too afraid to ask? Join those who have undergone the process as they give you the nuts and bolts of the pro…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
RT @ecalhoun21: https://t.co/ERExaJw1OV @aaeminfo WiEM webinar relevant this week for any #unmatched #embound 4th years.
-
-
Mashup Score: 25Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline - 11 month(s) ago
PURPOSE To develop recommendations for germline mutation testing for patients with breast cancer. METHODS An ASCO–Society of Surgical Oncology (SSO) panel convened to develop recommendations based on a systematic review and formal consensus process. RESULTS Forty-seven articles met eligibility criteria for the germline mutation testing recommendations; 18 for the genetic counseling recommendations. RECOMMENDATIONS BRCA1/2 mutation testing should be offered to all newly diagnosed patients with breast cancer ≤65 years and select patients >65 years based on personal history, family history, ancestry, or eligibility for poly(ADP-ribose) polymerase (PARP) inhibitor therapy. All patients with recurrent breast cancer who are candidates for PARP inhibitor therapy should be offered BRCA1/2 testing, regardless of family history. BRCA1/2 testing should be offered to women who develop a second primary cancer in the ipsilateral or contralateral breast. For patients with prior history of breast canc
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Updated @ASCO guidelines for Germline Testing in Patients With Breast Cancer. BRCA1/2 testing offered to all newly diagnosed ≤65 yrs and select patients >65 years based on personal history, family history, ancestry, or eligibility for PARPi #BCSM https://t.co/LfOh8RJxcz
-
-
Mashup Score: 22Beyond bacteria: How the intratumor mycobiome modulates lung adenocarcinoma progression - 1 year(s) ago
Increasing evidence suggests that tumors harbor diverse microbiomes, adding complexity to the tumor microenvironment. In this issue of Cancer Cell, Liu et al. highlight the role of the intratumor mycobiome, specifically Aspergillus sydowii, in promoting lung adenocarcinoma progression. A. sydowii enhances the recruitment and activation of myeloid-derived suppressor cells via IL-1β signaling driven by the β-glucan-mediated Dectin-1/CARD9 pathway.
Source: www.cell.comCategories: Latest Headlines, Oncologists2Tweet-
RT @Cancer_Cell: Online Now: Beyond bacteria: How the intratumor mycobiome modulates lung adenocarcinoma progression https://t.co/UZu9iRkjsy
-
-
Mashup Score: 1
KEYTRUDA® (pembrolizumab) plus chemotherapy before surgery significantly improved pCR rate compared to neoadjuvant placebo plus chemotherapy KEYNOTE-756 is the first positive Phase 3 study with an immunotherapy regimen to demonstrate a statistically significant improvement in pCR rate in the neoadjuvant setting for this patient population Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-756 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met one of its dual primary endpoints of pathological complete response (pCR) rate following the neoadjuvant part of the neoadjuvant/adjuvant study regimen in patients with high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. At a prespecified interim analysis conducted by an independent Data Monitoring Committee (DMC), the KEYTRUDA-based regimen demonstrated a
Source: www.merck.comCategories: Latest Headlines, Oncologists2Tweet-
Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer #BCSM #MedEd https://t.co/0whrQsoCFe
-
-
Mashup Score: 4THE ONCOALERT NETWORK - 2 year(s) ago
Welcome to OncoAlert
Source: THE ONCOALERT NETWORKCategories: Latest Headlines, Oncologists2Tweet-
RT @OncoAlert: The @OncoAlert 🚨 Newsletter for #ASCO23 Comes out Tomorrow for Day 1⃣of @ASCO Go to https://t.co/yzt83gqQkF and sign up‼️ C…
-
-
Mashup Score: 0WHO ends global health emergency declaration for COVID-19 - 2 year(s) ago
The World Health Organization today lifted its Public Health Emergency of International Concern for COVID-19. That declaration went into effect three years ago on Jan. 30, 2020.
Source: NPRCategories: Hem/Oncs, Latest HeadlinesTweet-
WHO ends global health emergency declaration for COVID-19. https://t.co/QLfEfcmr8Z
-
Can we prevent metastasis? Our @MontefioreNYC @EinsteinMed team just published results of the first-in-human trial targeting metastasis (TMEM) doorways in breast cancer. Thanks for all the mentorship, @jsparano #BCSM @OncoAlert https://t.co/fYoh8VkQMN